Geoffrey Meacham

New Capabilities

Citi maintained its Buy rating and $125 price target on BioNTech after the PFS miss

BioNTech's mRNA cancer drug BNT113, added to Merck's Keytruda, did not hold off HPV16-positive head and neck cancer longer than Keytruda alone. The miss, reported Oct. 13, was the first of the Phase 2/3 AHEAD-MERIT trial's two main goals, and US-listed BioNTech shares fell about 7% that day.

Updated Oct 30